Vagus nerve stimulation as a therapeutic option in inflammatory rheumatic diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and therapeutic potential with no new empirical data or systematic search methodology.
PubMed 37814148 · doi:10.1007/s00296-023-05477-1
What was done
This narrative review summarizes the neuro-immunological mechanisms linking the vagus nerve to inflammation control—including the cholinergic anti-inflammatory pathway mediated by alpha-7-nicotinic acetylcholine receptors on macrophages, hypothalamic-pituitary cortisol release, and splenic sympathetic regulation—and outlines the therapeutic application of vagus nerve stimulation in inflammatory rheumatic conditions.
What was found
The abstract reports purely mechanistic descriptions and conceptual rationale. No quantitative data, sample sizes, effect sizes, statistical metrics, or primary clinical trial outcomes are reported.
Why it matters
It highlights the biological rationale for using bioelectronic and neuro-modulatory approaches, specifically vagus nerve stimulation, as potential adjunctive therapies in inflammatory rheumatic diseases.
Limits
The paper is a narrative review that provides no original data or systematic synthesis. The abstract lacks clinical efficacy endpoints, safety and adverse event data, optimal stimulation protocols, and details on which specific rheumatic populations benefit most.
Cited by
- supports Phosphatidylcholine from lecithin serves as a precursor for acetylcholine, which is utilized in vagal nerve transmission.